Attention Pharmacists and Pharmacy Techs: Click to access CPE Monitor and CE information More Information
This activity will review the latest PK recommendations for Factor VIII and IX replacement and how to use and interpret PK parameters to assess treatment plans.
Choose from the criteria below to find an activity that fits you best.
In recent years, several over-the-counter emergency contraception products have entered the market. These include Plan B and other levonorgestrel-based generic alternatives. No longer are these products dispensed by pharmacists, nor are they subject to age restrictions, counseling requirements, and certain other guidelines that were imposed when Plan B was first approved. Yet, there is significant confusion, as well as misunderstanding and anxiety, among pharmacists as well as consumers regarding how emergency contraception works, when it can be effectively dispensed and used, and who can use it. It is essential that pharmacy professionals be able to consistently and authoritatively counsel patients about OTC emergency contraception products – regardless of whether the product is available OTC, behind-the-counter, or in a locked display. This CE activity provides pharmacists a thorough review of how these products are used, who may purchase them, and how they and their patients can obtain additional needed information.
Upon completion of this activity, participants will be able to:
Mary Lynn Moody, RPh
Clinical Associate Professor, Pharmacy Practice
Director, Business Development, Drug Information Center
University of Illinois at Chicago (UIC) College of Pharmacy
James H. Wisner, BBA, MBA
President, Wisner Marketing Group, Inc.
Release Date: 06-01-2015
Expiration Date: 06-01-2018
This CE activity is jointly provided by ProCE, Inc. and Wisner Marketing Group. ProCE is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-9999-15-100-H01-P has been assigned to this knowledge-based home-study CE activity (initial release date 06-01-15). This activity is approved for 1.0 contact hour (0.1 CEU) in states that recognize ACPE providers. Completion of the evaluation and the post-test with a score of 70% or higher are required to receive CE credit. No partial credit will be given.
This activity is supported by an educational grant from Perrigo.
It is the policy of ProCE, Inc. to ensure balance, independence, objectivity and scientific rigor in all of its continuing education activities. Faculty must disclose to participants any significant financial interest or affiliation with companies that manufacture or market products discussed in this activity. Mr. Wisner and Ms. Moody have disclosed that they have served as a consultant and/or speaker for the Perrigo Company.
Please note: The information and views presented in this activity are those of the faculty through clinical practice and knowledge of the professional literature. Portions of this activity may include the use of drugs and/or devices for unlabeled indications, which should be considered experimental. Participants are advised to consult manufacturer product information and the professional literature, and use professional judgment in applying the presented information in patient-care activities.
The material presented in this CE activity does not reflect the views of ProCE, Inc. or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.